The dual-targeting TKI Lapatinib, which inhibits both EGFR and ErbB2, is approved for use in ErbB2 positive breast cancer upon relapse following treatment standard chemotherapy and trastuzumab (Nolting et al., 2014). Here, EGFR is linked to breast carcinoma.